在许多特定的临床情况下，患者和外科医生需要使应用生物骨材料的益处和作为优化临床管理的移植材料性能特征风险预测之间达成平衡。
In any given clinical situation, the patient and surgeon need to balance the benefits and performance characteristics of the graft material with the risk profile to optimize clinical management.
经过几十年的不断完善，此疗法已在技术上完全成熟，并被众多的欧洲医生广泛应用于临床。
After decades of practice and improvement, the therapy has completely reached maturity and been widely applied in clinic cases by European Medical Community.
ATP3是额外的努力，并且推动了胆固醇研究领域的研究进展，但是在目前2011年，许多主要的临床医生希望指南能够更容易应用。
The ATP3 was an extraordinary effort and took the cholesterol field forward, but now in 2011, many primary clinicians want guidelines that are simpler to use.
应用推荐